<?xml version='1.0' encoding='utf-8'?>
<document id="22147075"><sentence text="The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers."><entity charOffset="14-25" id="DDI-PubMed.22147075.s1.e0" text="dacomitinib" /></sentence><sentence text="This study evaluated the effect of a single 45-mg dose of dacomitinib (PF-00299804), an irreversible small-molecule inhibitor of human epidermal growth factor receptors-1, -2, and -4, on CYP2D6 activity in healthy volunteers (HV) using dextromethorphan (DM), a selective CYP2D6 probe"><entity charOffset="58-69" id="DDI-PubMed.22147075.s2.e0" text="dacomitinib" /><entity charOffset="236-252" id="DDI-PubMed.22147075.s2.e1" text="dextromethorphan" /><entity charOffset="254-256" id="DDI-PubMed.22147075.s2.e2" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s2.e0" e2="DDI-PubMed.22147075.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22147075.s2.e0" e2="DDI-PubMed.22147075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s2.e0" e2="DDI-PubMed.22147075.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s2.e1" e2="DDI-PubMed.22147075.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s2.e1" e2="DDI-PubMed.22147075.s2.e2" /></sentence><sentence text="" /><sentence text="Fourteen male HVs were enrolled in this open-label, randomized, cross-over, single-dose study of DM alone or with dacomitinib"><entity charOffset="114-125" id="DDI-PubMed.22147075.s4.e0" text="dacomitinib" /><entity charOffset="97-107" id="DDI-PubMed.22147075.s4.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s4.e1" e2="DDI-PubMed.22147075.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s4.e1" e2="DDI-PubMed.22147075.s4.e0" /></sentence><sentence text=" Each HV received both treatments separated by a 14-day washout period" /><sentence text=" The pharmacokinetics of DM, dextrorphan (DX; the major DM metabolite), dacomitinib and PF-05199265 (an active metabolite of dacomitinib) were calculated"><entity charOffset="25-27" id="DDI-PubMed.22147075.s6.e0" text="DM" /><entity charOffset="29-40" id="DDI-PubMed.22147075.s6.e1" text="dextrorphan" /><entity charOffset="42-44" id="DDI-PubMed.22147075.s6.e2" text="DX" /><entity charOffset="72-83" id="DDI-PubMed.22147075.s6.e3" text="dacomitinib" /><entity charOffset="125-136" id="DDI-PubMed.22147075.s6.e4" text="dacomitinib" /><entity charOffset="56-66" id="DDI-PubMed.22147075.s6.e5" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e0" e2="DDI-PubMed.22147075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e1" e2="DDI-PubMed.22147075.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e1" e2="DDI-PubMed.22147075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e1" e2="DDI-PubMed.22147075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e1" e2="DDI-PubMed.22147075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e1" e2="DDI-PubMed.22147075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e2" e2="DDI-PubMed.22147075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e2" e2="DDI-PubMed.22147075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e2" e2="DDI-PubMed.22147075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e2" e2="DDI-PubMed.22147075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e5" e2="DDI-PubMed.22147075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e5" e2="DDI-PubMed.22147075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e5" e2="DDI-PubMed.22147075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e3" e2="DDI-PubMed.22147075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22147075.s6.e3" e2="DDI-PubMed.22147075.s6.e4" /></sentence><sentence text="" /><sentence text="When combined with dacomitinib, the ratio of adjusted geometric means (90% CI) of DM area under the concentration-time curve (AUC)(last) was 955% (90% CI: 560%, 1,630%) and maximum plasma concentration (C (max)) was 973% (90% CI: 590%, 1,606%), compared with DM alone"><entity charOffset="19-30" id="DDI-PubMed.22147075.s8.e0" text="dacomitinib" /><entity charOffset="82-92" id="DDI-PubMed.22147075.s8.e1" text="DM" /><entity charOffset="259-269" id="DDI-PubMed.22147075.s8.e2" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s8.e0" e2="DDI-PubMed.22147075.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22147075.s8.e0" e2="DDI-PubMed.22147075.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s8.e0" e2="DDI-PubMed.22147075.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s8.e1" e2="DDI-PubMed.22147075.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s8.e1" e2="DDI-PubMed.22147075.s8.e2" /></sentence><sentence text=" For dacomitinib plus DM, exposures were consistent with those in patients receiving single-dose dacomitinib"><entity charOffset="97-108" id="DDI-PubMed.22147075.s9.e0" text="dacomitinib" /><entity charOffset="22-32" id="DDI-PubMed.22147075.s9.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s9.e1" e2="DDI-PubMed.22147075.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s9.e1" e2="DDI-PubMed.22147075.s9.e0" /></sentence><sentence text=" Terminal elimination half-life (t (1/2)) was 51" /><sentence text="4 h" /><sentence text=" Mild and moderate treatment-related adverse events were reported" /><sentence text=" No HV withdrew from the study" /><sentence text="" /><sentence text="Single-dose administration of dacomitinib plus DM was safe and well tolerated in HVs and resulted in a significant increase in systemic exposures of DM in extensive metabolizers"><entity charOffset="30-41" id="DDI-PubMed.22147075.s15.e0" text="dacomitinib" /><entity charOffset="47-57" id="DDI-PubMed.22147075.s15.e1" text="DM" /><entity charOffset="149-159" id="DDI-PubMed.22147075.s15.e2" text="DM" /><pair ddi="false" e1="DDI-PubMed.22147075.s15.e0" e2="DDI-PubMed.22147075.s15.e0" /><pair ddi="false" e1="DDI-PubMed.22147075.s15.e0" e2="DDI-PubMed.22147075.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s15.e0" e2="DDI-PubMed.22147075.s15.e2" /><pair ddi="false" e1="DDI-PubMed.22147075.s15.e1" e2="DDI-PubMed.22147075.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22147075.s15.e1" e2="DDI-PubMed.22147075.s15.e2" /></sentence><sentence text=" No effect was observed on the pharmacokinetics of dacomitinib"><entity charOffset="51-62" id="DDI-PubMed.22147075.s16.e0" text="dacomitinib" /></sentence><sentence text=" Drug-drug interaction may occur when dacomitinib is concomitantly administered with therapeutic agents metabolized by cytochrome P450 (CYP) 2D6" /><sentence text=" Administration of drugs which are highly dependent on CYP2D6 metabolism may require dose adjustment, or substitution with an alternative medication" /><sentence text="" /></document>